Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/IIa clinical trial targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase I clinical trials for the treatment of diabetic macular edema. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
IPO Year: 2019
Exchange: NASDAQ
Website: bicycletherapeutics.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
11/8/2024 | $25.00 | Equal-Weight | Stephens |
9/6/2024 | $35.00 | Outperform | RBC Capital Mkts |
8/7/2024 | $33.00 → $28.00 | Buy → Neutral | B. Riley Securities |
9/11/2023 | Neutral → Buy | B. Riley Securities | |
8/31/2022 | Outperform | Cowen | |
7/28/2022 | $30.00 | Overweight | Barclays |
7/6/2022 | $60.00 | Buy | Canaccord Genuity |
4/13/2022 | $62.00 → $33.00 | Buy → Neutral | B. Riley Securities |
4/7/2022 | $100.00 → $80.00 | Overweight | Cantor Fitzgerald |
3/3/2022 | $85.00 → $70.00 | Market Outperform | JMP Securities |
4 - BICYCLE THERAPEUTICS PLC (0001761612) (Issuer)
4 - BICYCLE THERAPEUTICS PLC (0001761612) (Issuer)
4 - BICYCLE THERAPEUTICS PLC (0001761612) (Issuer)
4 - BICYCLE THERAPEUTICS PLC (0001761612) (Issuer)
4 - BICYCLE THERAPEUTICS PLC (0001761612) (Issuer)
4 - BICYCLE THERAPEUTICS PLC (0001761612) (Issuer)
4 - BICYCLE THERAPEUTICS PLC (0001761612) (Issuer)
4 - BICYCLE THERAPEUTICS PLC (0001761612) (Issuer)
4 - BICYCLE THERAPEUTICS PLC (0001761612) (Issuer)
4 - BICYCLE THERAPEUTICS PLC (0001761612) (Issuer)
10-Q - BICYCLE THERAPEUTICS PLC (0001761612) (Filer)
8-K - BICYCLE THERAPEUTICS PLC (0001761612) (Filer)
8-K - BICYCLE THERAPEUTICS PLC (0001761612) (Filer)
8-K - BICYCLE THERAPEUTICS PLC (0001761612) (Filer)
S-8 - BICYCLE THERAPEUTICS PLC (0001761612) (Filer)
10-Q - BICYCLE THERAPEUTICS PLC (0001761612) (Filer)
8-K - BICYCLE THERAPEUTICS PLC (0001761612) (Filer)
8-K - BICYCLE THERAPEUTICS PLC (0001761612) (Filer)
8-K - BICYCLE THERAPEUTICS PLC (0001761612) (Filer)
424B7 - BICYCLE THERAPEUTICS PLC (0001761612) (Filer)
Bicycle Therapeutics plc (NASDAQ:BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Nov. 19, 2024, at 10:30 a.m. GMT. A live webcast of the fireside chat will be accessible from the Investor section of the company's website at www.bicycletherapeutics.com. A replay of the webcast will be archived and available following the event. About Bicycle Therapeutics Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines, referred t
Bicycle Therapeutics plc (NASDAQ:BCYC), today announced that on November 1, 2024, the Compensation Committee of the company's Board of Directors granted to twelve new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 56,700 ordinary shares. These awards were made under Bicycle Therapeutics' 2024 Inducement Plan and approved by the Compensation Committee as an inducement material to the employees entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). Each option has an exercise price equal to $23.44 per share, Bicycle Therapeutics' closing trading price on October 31, 2024, and will vest over four years, w
Presented updated clinical results across oncology pipeline, including a 45% overall response rate (ORR) for zelenectide pevedotin monotherapy and a 45% ORR for BT5528 6.5 mg/m2 every two weeks monotherapy, both in metastatic urothelial cancer Progressed radiopharmaceuticals pipeline with first human imaging data validating the potential of MT1-MMP as a novel cancer target and outlined company strategy in this area Cash and cash equivalents of $890.9 million as of September 30, 2024, excluding $31.7 million UK R&D tax credit received in October 2024; expected financial runway into 2H 2027 Bicycle Therapeutics plc (NASDAQ:BCYC), a pharmaceutical company pioneering a new and differentiated
First human imaging data validate the potential of MT1-MMP as a novel target in the treatment of cancer and demonstrate positive properties of Bicycle Radionuclide Conjugates (BRC®) for radiopharmaceutical use Additional preclinical data demonstrate biodistribution of BRCs can be optimized to maintain high tumor uptake while significantly reducing kidney levels Company strategy focuses on pursuing novel targets using a range of isotopes to develop radiopharmaceuticals with first-in-class potential Bicycle Therapeutics to host conference call and webcast today at 8 a.m. ET Bicycle Therapeutics plc (NASDAQ:BCYC), a pharmaceutical company pioneering a new and differentiated class of therap
Company to host conference call and webcast on Wednesday, Oct. 23, at 8 a.m. ET to review the data and outline radiopharmaceuticals strategy Bicycle Therapeutics plc (NASDAQ:BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that the company will present data highlighting its potential to develop differentiated radiopharmaceutical molecules, called Bicycle Radionuclide Conjugates (BRC®), at the European Association of Nuclear Medicine (EANM) 2024 Congress taking place October 19-23 in Hamburg, Germany. The German Cancer Consortium (DKTK), part of a cooperative network wi
Bicycle Therapeutics plc (NASDAQ:BCYC), today announced that on October 1, 2024, the Compensation Committee of the company's Board of Directors granted to eight new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 47,600 ordinary shares. These awards were made under Bicycle Therapeutics' 2024 Inducement Plan and approved by the Compensation Committee as an inducement material to the employees entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). Each option has an exercise price equal to $22.63 per share, Bicycle Therapeutics' closing trading price on September 30, 2024, and will vest over four years, w
Updated monotherapy data for Nectin-4 targeting zelenectide pevedotin in metastatic urothelial cancer (mUC) showed a promising 45% overall response rate (ORR), 11.1 months median duration of response and a generally well-tolerated safety profile EphA2-targeting BT5528 demonstrated an emerging differentiated safety profile and antitumor activity in patients with advanced solid tumors, including a 45% ORR in mUC 6.5 mg/m2 every two weeks dose expansion cohort Relatively low frequency and severity of treatment-related peripheral neuropathy following monotherapy with Bicycle Toxin Conjugates® zelenectide pevedotin and BT5528, with patients often able to continue therapy without modification
Bicycle Therapeutics plc (NASDAQ:BCYC), today announced that on September 3, 2024, the Compensation Committee of the company's Board of Directors granted to seven new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 29,500 ordinary shares. These awards were made under Bicycle Therapeutics' 2024 Inducement Plan and approved by the Compensation Committee as an inducement material to the employees entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). Each option has an exercise price per share equal to $21.50 per share, Bicycle Therapeutics' closing trading price on August 30, 2024, and will vest over fou
Bicycle Therapeutics plc (NASDAQ:BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in the following investor conferences in September: Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, Sept. 4; fireside chat at 8:30 a.m. ET 2024 Cantor Global Healthcare Conference on Wednesday, Sept. 18; fireside chat at 11:30 a.m. ET Live webcasts of the fireside chats will be accessible in the Investor section of the company's website at www.bicycletherapeutics.com. Archived replays of the webcasts will be available following
Four abstracts containing data updates across clinical pipeline accepted for poster presentation at ESMO Congress 2024 Focused R&D pipeline on clinical programs and research areas that have the highest potential to maximize value creation Streamlined leadership team to better align with strategic and pipeline priorities, and enhanced oncology expertise with formation of Clinical Advisory Board Strengthened balance sheet with gross proceeds of approximately $555 million from May 2024 private investment in public equity (PIPE) financing Cash and cash equivalents of $961.4 million as of June 30, 2024, expected to provide financial runway into 2H 2027 Bicycle Therapeutics plc (NASDAQ:
- SEC Filing
U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling more than 550 points on Thursday. The Dow traded down 1.44% to 39,098.81 while the NASDAQ fell 0.39% to 16,735.32. The S&P 500 also fell, dropping, 0.69% to 5,270.47. Check This Out: How To Earn $500 A Month From Ross Stores Stock Ahead Of Q1 Earnings Leading and Lagging SectorsInformation technology shares rose by 1.5% on Thursday. In trading on Thursday, real estate shares fell by 1.3%. Top Headline BJ's Wholesale Club Holdings, Inc. (NYSE:BJ) reported better-than-expected results for its first quarter on Thursday. The company posted quarterly revenue growth of 4.1% year-on-year to $4
U.S. stocks traded mixed midway through trading, with the Dow Jones index falling more than 250 points on Thursday. The Dow traded down 0.65% to 39,414.01 while the NASDAQ rose 0.84% to 16,942.51. The S&P 500 also rose, gaining, 0.24% to 5,319.63. Check This Out: How To Earn $500 A Month From Ross Stores Stock Ahead Of Q1 Earnings Leading and Lagging SectorsInformation technology shares rose by 1.3% on Thursday. In trading on Thursday, real estate shares fell by 1.1%. Top Headline The S&P Global manufacturing PMI rose to 50.9 in May from 50 in April, while services PMI climbed to 54.8 in May from 51.3. The S&P Global composite PMI jumped to 54.4 in May compared to 51.3
U.S. stocks were mixed, with the Dow Jones index falling around 250 points on Thursday. Shares of e.l.f. Beauty, Inc. (NYSE:ELF) rose sharply during Thursday's session after the company reported better-than-expected fourth-quarter earnings. e.l.f. Beauty reported adjusted earnings of 53 cents per share, beating the 32-cent estimate, according to data from Benzinga Pro. Quarterly sales clocked in at $321.14 million, beating the $292.17 million analyst consensus estimate, primarily driven by strength across retailer and e-commerce channels. e.l.f. Beauty said it sees fiscal year earnings between $3.20 and $3.25 per share, versus the $3.51 per share estimate, and full-year revenue in a
Gainers OneMedNet (NASDAQ:ONMD) shares moved upwards by 103.2% to $1.0 during Thursday's pre-market session. The company's market cap stands at $23.7 million. iSpecimen (NASDAQ:ISPC) stock moved upwards by 30.67% to $0.41. The market value of their outstanding shares is at $4.1 million. P3 Health Partners (NASDAQ:PIII) stock increased by 25.51% to $0.63. The company's market cap stands at $75.3 million. Bicycle Therapeutics (NASDAQ:BCYC) stock increased by 12.04% to $24.0. The company's market cap stands at $913.7 million. Calliditas Therapeutics (NASDAQ:CALT) stock moved upwards by 11.42% to $24.19. The market value of their outstanding shares is at $649.1 million. The company's, Q1 ea
The company has entered into a securities purchase agreement with certain existing and new accredited investors to issue and sell an aggregate of 25.933 million American Depositary Shares, each representing one ordinary share, and in lieu of ADSs to investors that so choose, non-voting ordinary shares, each at a price of $21.42 per share, through a private investment in public equity ("PIPE") financing. Bicycle anticipates the gross proceeds from the PIPE to be approximately $555 million. The financing is expected to close on May 28, 2024, subject to customary closing conditions.
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Bicycle Therapeutics (NASDAQ:BCYC) with a Buy and maintains $55 price target.
Bicycle Therapeutics (NASDAQ:BCYC) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(1.31) by 52.67 percent. This is a 52.31 percent increase over losses of $(1.30) per share from the same period last year. The company reported quarterly sales of $19.530 million which beat the analyst consensus estimate of $6.029 million by 223.91 percent. This is a 298.90 percent increase over sales of $4.896 million the same period last year.
Stephens initiated coverage of Bicycle Therapeutics with a rating of Equal-Weight and set a new price target of $25.00
RBC Capital Mkts initiated coverage of Bicycle Therapeutics with a rating of Outperform and set a new price target of $35.00
B. Riley Securities downgraded Bicycle Therapeutics from Buy to Neutral and set a new price target of $28.00 from $33.00 previously
B. Riley Securities upgraded Bicycle Therapeutics from Neutral to Buy
Cowen initiated coverage of Bicycle Therapeutics with a rating of Outperform
Barclays initiated coverage of Bicycle Therapeutics with a rating of Overweight and set a new price target of $30.00
Canaccord Genuity resumed coverage of Bicycle Therapeutics with a rating of Buy and set a new price target of $60.00
B. Riley Securities downgraded Bicycle Therapeutics from Buy to Neutral and set a new price target of $33.00 from $62.00 previously
Cantor Fitzgerald resumed coverage of Bicycle Therapeutics with a rating of Overweight and set a new price target of $80.00 from $100.00 previously
JMP Securities reiterated coverage of Bicycle Therapeutics with a rating of Market Outperform and set a new price target of $70.00 from $85.00 previously
SC 13G/A - BICYCLE THERAPEUTICS PLC (0001761612) (Subject)
SC 13G/A - BICYCLE THERAPEUTICS PLC (0001761612) (Subject)
SC 13G/A - BICYCLE THERAPEUTICS PLC (0001761612) (Subject)
SC 13G - BICYCLE THERAPEUTICS plc (0001761612) (Subject)
SC 13D/A - BICYCLE THERAPEUTICS plc (0001761612) (Subject)
SC 13D - BICYCLE THERAPEUTICS plc (0001761612) (Subject)
SC 13G/A - BICYCLE THERAPEUTICS plc (0001761612) (Subject)
SC 13G/A - BICYCLE THERAPEUTICS plc (0001761612) (Subject)
SC 13G - BICYCLE THERAPEUTICS plc (0001761612) (Subject)
SC 13G/A - BICYCLE THERAPEUTICS plc (0001761612) (Subject)
First human imaging data validate the potential of MT1-MMP as a novel target in the treatment of cancer and demonstrate positive properties of Bicycle Radionuclide Conjugates (BRC®) for radiopharmaceutical use Additional preclinical data demonstrate biodistribution of BRCs can be optimized to maintain high tumor uptake while significantly reducing kidney levels Company strategy focuses on pursuing novel targets using a range of isotopes to develop radiopharmaceuticals with first-in-class potential Bicycle Therapeutics to host conference call and webcast today at 8 a.m. ET Bicycle Therapeutics plc (NASDAQ:BCYC), a pharmaceutical company pioneering a new and differentiated class of therap
Company to host conference call and webcast on Wednesday, Oct. 23, at 8 a.m. ET to review the data and outline radiopharmaceuticals strategy Bicycle Therapeutics plc (NASDAQ:BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that the company will present data highlighting its potential to develop differentiated radiopharmaceutical molecules, called Bicycle Radionuclide Conjugates (BRC®), at the European Association of Nuclear Medicine (EANM) 2024 Congress taking place October 19-23 in Hamburg, Germany. The German Cancer Consortium (DKTK), part of a cooperative network wi
Alignment with U.S. FDA on design of Phase 2/3 registrational trial, to be initiated in 1Q 2024 Innovative study design allows for potential accelerated approval in untreated (first-line) and previously treated (second-line plus) metastatic bladder cancer Conference call and webcast today at 8 a.m. ET Bicycle Therapeutics (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the company will proceed with its plan to expedite development of BT8009 for metastatic bladder (urothelial) cancer following recent discussions with the U.S. Food and Drug Administration (FD
50% overall response rate (ORR) and 75% clinical benefit rate, including one complete response in urothelial cancer at the 5 mg/m2 dose on an intent-to-treat (ITT) basis As of January 2023, median duration of response (mDOR) is estimated to be approximately 14 months among urothelial cancer patients in the 5 mg/m2 cohort Confirmed RECIST responses in non-small cell lung cancer (NSCLC) and breast cancer patients Conference call scheduled for 8:00 a.m. ET Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced monotherapy Phase I dose escalatio
- Company to Host Conference Call on February 14 at 8:00 a.m. ET - Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that monotherapy dose escalation results of the ongoing Phase I/II trial of BT8009, a second-generation BTC™ targeting Nectin-4, will be presented at the 2023 American Society for Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, being held February 16-18, 2023 in San Francisco, California. On Tuesday, February 14, 2023 at 8:00 a.m. ET, the Company will host a conference call with BT8009 investigator Dr. Capucin
Anti-tumor activity observed in heavily pre-treated patients with EphA2-positive ovarian and urothelial cancers; overall response rates of 22% (including one complete response) and 67%, respectively Emergent safety profile of BT5528 suggests notable differentiation from current and prior generation EphA2 targeted molecules, with no treatment-related hemorrhage and low grade, low incidence of peripheral neuropathy, skin rash, and eye disorders Enrollment in BT5528 expansion cohorts at the recommended Phase II dose (RP2D) of 6.5mg/m2 every other week remains ongoing Conference call scheduled for 8:30 a.m. ET Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new
- 50% confirmed overall response rate, including one (13%) confirmed complete response in eight urothelial cancer patients dosed at 5.0mg/m2 weekly - Median duration of response not yet reached in the 2.5mg/m2 and 5.0mg/m2 weekly cohorts; four of five responders in these cohorts still on therapy after at least 24 weeks - Tolerability profile maintained over time, with low incidence of skin, ocular and neurological toxicities showing potential for differentiation from antibody-based approaches - Company to Host Conference Call Today at 8:30 a.m. ET Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its propri
- Company to Host Conference Call on Monday, April 11, 2022 at 8:30 a.m. ET Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that interim Phase I results from the Phase I/II trial of BT8009, a second-generation BTC™ targeting Nectin-4, will be presented at the 2022 American Association for Cancer Research Annual Meeting, being held April 8-13, 2022 in New Orleans, LA. The Company will host a conference call to discuss the data from the presentation on Monday, April 11, 2022 at 8:30 a.m. ET. Oral Presentation Details Title: BT8009-100 Ph
- Four Additional Abstracts Selected as Poster Presentations at the Meeting - Company to Host Conference Call on Monday, April 11, 2022 at 8:30 a.m. ET Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that interim Phase I results from the Phase I/II trial of BT8009, a second-generation BTC™ targeting Nectin-4, has been selected for an oral presentation at the upcoming 2022 American Association for Cancer Research Annual Meeting, being held April 8-13, 2022 in New Orleans, LA. The Company will host a conference call to discuss the data fr
- BT5528 Phase I anti-tumor activity observed in late line patients, with 2 partial responses out of 2 urothelial cancer patients dosed and an 80% disease control rate in 5 EphA2-positive ovarian cancer patients, including 1 partial response - A recommended BT5528 Phase II dose (RP2D) range has been established at 6.5-8.5mg/m2 every other week; expansion cohorts expected to initiate in 2022 - In the ongoing BT8009 Phase I trial in monotherapy cohorts, 4 out of 11 urothelial patients had partial responses; Phase I dose escalation remains ongoing, with no dose limiting toxicities (DLTs) yet observed - BT5528 data to be presented at a virtual plenary session today at 1:25pm ET at the AACR-N
EDINBURGH and CAMBRIDGE, United Kingdom, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Macomics Ltd, a leader in macrophage drug discovery, announces that it has appointed Kevin Lee Ph.D., MBA as Independent Non-Executive Director. Based in the UK and CEO of Cambridge, UK/Cambridge, US based, Bicycle Therapeutics (NASDAQ:BCYC), Kevin brings two decades of biotech and pharma experience to Macomics. In addition to his seat on Bicycle's board of directors, he is also a non-executive director of Alchemab Therapeutics Ltd. Kevin has led Bicycle Therapeutics since 2015, steering it through its strategic growth including various collaborations and financings including through its listing on NAS
Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the appointment of Alethia Young as its new Chief Financial Officer, effective July 17th. Ms. Young joins Bicycle from Graphite Bio, where she served as Chief Financial Officer, and previously served as senior biotech analyst and head of research at Cantor Fitzgerald. "We are thrilled to welcome Alethia to Bicycle and believe her experience and insights will make her an invaluable addition to our team," said Kevin Lee, Ph.D., Chief Executive Officer of Bicycle Therapeutics. "Alethia is a se
- Santiago Arroyo, M.D., Ph.D., appointed Chief Development Officer - Jennifer Perry, Pharm.D., promoted to Senior Vice President, Commercial Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the appointment of Santiago Arroyo, M.D., Ph.D., as Chief Development Officer, effective March 31. In addition, Jennifer Perry, PharmD, has been promoted to Senior Vice President, Commercial. Dr. Arroyo brings to Bicycle over 20 years of biopharmaceutical industry experience, leading the clinical development of therapeutics across multiple disease a
- BT7480, the lead Bicycle tumor-targeted immune cell agonist, presented at AACR Annual Meeting 2021 "New Drugs on the Horizon" session; remains on-track for 2H'21 clinical trial start - Achieved significant recent progress across pipeline of Bicycle®-based therapies beyond oncology - Raised $75.0 million through at-the-market offering program; cash of $195.9 million as of March 31, 2021 expected to provide financial runway through multiple clinical milestones and into 2024 Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial resul
Ikena Oncology, Inc. (NASDAQ:IKNA) ("Ikena"), a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer, today announced the appointment of Maria Koehler, M.D., Ph.D. to its Board of Directors. Dr. Koehler is a board-certified hematologist and oncologist with more than 20 years of pharmaceutical and biotech oncology experience in clinical development, including senior roles at Pfizer where she led the development of Ibrance® (palbociclib) and contributed to the strategic direction of the oncology portfolio. "We are extremely pleased to welcome Maria to our Board of Directors at this important next stage
CAMBRIDGE, England, & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the appointment of Jose-Carlos (“JC”) Gutierrez-Ramos, Ph.D., to its Board of Directors. Dr. Gutierrez-Ramos previously served as the Chair of Bicycle’s Scientific Advisory Board and has extensive experience in leading biopharmaceutical companies and scientific groups in the world's top academic institutions. “We are delighted to welcome JC back to the Bicycle team as a Board member. JC has dedicated his entire career, most of it in
Advancing Clinical Development of Next Generation Diabetic Macular Edema (DME) Therapies – with Novel MoAs Beyond anti-VEGF Recruiting Phase 2 study (‘KALAHARI’) evaluating THR-149, a potent plasma kallikrein inhibitor in DME – On track for Part A data by mid-year Positive data from Phase 1 study evaluating THR-687, potential best in class pan-RGD integrin antagonist in DME – On track to start Phase 2 by mid-year Highlights Industry-leading pipeline targeting a total potential market opportunity of $12 billion in retinal vascular disorders First patients dosed in Phase 2 study (‘KALAHARI’) evaluating multiple injections of THR-149, a potent plasma kallik
Leuven, BE and Boston, MA, US - January 20, 2021 – 08.00 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care ophthalmic therapies, with a focus on diabetic macular edema (DME), is pleased to announce the appointment of Professor Alan Stitt, Ph.D. as the company’s Chief Scientific Officer (CSO), effective January 19, 2021. This appointment follows the retirement of current CSO Jean Feyen, PhD, who has served in this position since joining the company in 2013. Dr. Feyen will remain available to the company during a transition period to support Professor Stitt and the rest of the pre-clinical development team. Professo